Navigation Links
Egenix Licenses Harvard Anti-Cancer Platform
Date:1/31/2008

MILLBROOK, N.Y., Jan. 31 /PRNewswire/ -- Mr. Donald Fresne, Chairman and CEO of Egenix, Inc., announced today that the company has recently obtained from Harvard University a field-exclusive license under patent rights that cover certain technologies related to cancer therapy and prognostic testing. The licensed technologies, which were developed jointly by scientists in the Laboratory for Translational Research and the Department of Biological Chemistry and Molecular Pharmacology, each of Harvard Medical School, comprise small molecule inhibitors of translation initiation, a new paradigm in target- specific, non-cytotoxic anti-cancer therapy, and the use of translation initiation-specific biomarkers to assess tumor sensitivity to anti-cancer therapy with this novel class of anti-cancer drugs. Specifically, the inhibitors of translation initiation licensed by Egenix from Harvard Medical School target the eIF4F and ternary complexes, the two critical regulators of messenger RNA translation into protein.

The company's management believes that small molecules for the inhibition of translation initiation are at the forefront of modern cancer therapeutics currently under development and that this cutting-edge platform has the potential to yield significant breakthroughs in the biomedical field for the treatment of cancer.

About Egenix, Inc.

Based in Millbrook, New York, Egenix, Inc. is a privately held biotechnology company responding to the demand for more effective cancer therapies.

Terms and conditions of the license agreement are not disclosed.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
2. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
3. Prometheus Licenses COLAL-PRED(R) From Alizyme
4. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
5. Syngenta Licenses Chromatin Gene Stacking Technology
6. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
7. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
8. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
9. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
10. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):